|
ICPA Health Products Ltd (ICPA), a leading pharma company in the oral healthcare segment, has launched its latest oral healthcare product– Mucofibro. Available in the form of soft-gel capsules, the product is targeted towards promoting the healing of a variety of oral lesions and improving the treatment outcomes of both, non-surgical and surgical dental procedures.
Mucofibro helps prevent the malignant transformation of precancerous lesions like oral leukoplakia and erythroplakia and also improves the treatment outcomes in precancerous conditions like oral submucous fibrosis (OSMF). The product is a recommended supplementation for improved clinical results in a variety of oral, periodontal and implant surgical procedures.
Packed with powerful antioxidants, carotenoids and minerals, Mucofibro prevents cell damage by fighting the oxidative stress inside the cells and restores the tissue healing capacity. With its powerful ‘cell detoxification action’ Mucofibro is beneficial in improving the clinical outcomes in non-cancer, pre-cancer and cancer treatments.
“India is considered the world capital for oral cancer contribution with one-third of the global burden. Mucofibro will play a big role in preventing the malignant transformation of precancerous lesions like oral leukoplakia and erythroplakia, and improving the treatment outcomes in precancerous conditions like oral submucous fibrosis where the common symptoms are burning mouth and reduced mouth opening. With its expanding scope in periodontics and implantology because of the new scientific evidence, Mucofibro aims to improve the clinical results in periodontology and the rapidly growing dental implantology segment,” says Abha Damani, Director, ICPA.
The nutritional supplement product category is valued at Rs.101 crore and has witnessed a positive growth in both its revenue at 14 per cent and the unit growth at 2 per cent. Each soft gelatin capsule contains lycopene - 5 mg, beta-carotene - 10 mg, alpha lipoic acid 50 mg, elemental copper - 1 mg, elemental selenium - 75 mcg, vitamin E - 10IU and zinc sulphate - 27.45 mg.
“With the introduction of Mucofibro, ICPA aims to capture a lion’s share of dental practice including general dental practitioners & specialists in oral medicine radiology, oral & maxillofacial surgery, periodontics and implantology, general medical practitioners, ENT, and oncology specialists,” concluded Damani.
The product will be available across all leading pharmacies in the country as well as through popular e-pharmacies.
|